Scarica l'app Stockscreener
51.11
0.12%
-0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Cantor Fitzgerald reiterates Overweight rating on Supernus Pharmaceuticals stock By Investing.com - Investing.com UK
Will Supernus Pharmaceuticals Inc. stock deliver long term returnsEarnings Performance Report & Verified Swing Trading Watchlist - ulpravda.ru
Why retail investors pile into Supernus Pharmaceuticals Inc. stockJuly 2025 Drop Watch & Technical Buy Zone Confirmation - ulpravda.ru
Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance
Investment Recap: How Supernus Pharmaceuticals Inc stock compares to growth peersProduct Launch & Weekly High Momentum Picks - moha.gov.vn
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Unlocking a 24% Potential Upside in the CNS Market - DirectorsTalk Interviews
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
(SUPN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Supernus Pharmaceuticals Earnings Notes - Trefis
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
SUPN (Supernus Pharmaceuticals) EV-to-OCF : 37.98 (As of Dec. 25, 2025) - GuruFocus
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Insider Sold Shares Worth $1,008,150, According to a Recent SEC Filing - marketscreener.com
Supernus Pharmaceuticals Senior VP Sells Shares - TradingView — Track All Markets
Supernus Pharmaceuticals (SUPN) Is Up 6.0% After FDA Approval Of ONAPGO Parkinson’s DrugHas The Bull Case Changed? - Sahm
Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) t - GuruFocus
Stifel raises Supernus Pharmaceuticals stock price target to $55 from $50 - Investing.com Canada
How Supernus Pharmaceuticals Inc. stock performs after earningsPortfolio Risk Report & Long Hold Capital Preservation Tips - Bölüm Sonu Canavarı
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 - Finviz
Why The OLB Group, Inc. stock attracts strong analyst attention - DonanımHaber
How risky is Supernus Pharmaceuticals Inc. stock nowJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - Улправда
Is Supernus Pharmaceuticals Inc. stock overvalued by current metrics2025 Market Outlook & AI Driven Price Predictions - Улправда
Has the Market Fully Recognized Supernus Pharmaceuticals’ Strong Run and Growth Prospects in 2025? - Yahoo Finance
Supernus Pharmaceuticals (SUPN): Assessing Valuation After a 33% One-Year Return and Undervalued Narrative - Yahoo Finance
SUPN to Participate in Cantor Fitzgerald Virtual Meeting - GuruFocus
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back - Yahoo Finance
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back - The Motley Fool
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? - MSN
(SUPN) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Supernus Pharmaceuticals Reports Strong Q3 2025 Growth - MSN
Supernus Pharmaceuticals Says Postpartum Depression Treatment Receives Authorization From Health Canada - marketscreener.com
Can Supernus Pharmaceuticals Inc. stock resist market sell offsRate Hike & Scalable Portfolio Growth Ideas - Newser
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics ... - Enidnews.com
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewswire
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Responsive Playbooks and the SUPN Inflection - news.stocktradersdaily.com
Supernus Pharmaceuticals Inc Stock Analysis and ForecastMerger & Acquisition Updates & Buy Sell Signal Notifications - earlytimes.in
Reversal Confirmed Inter Globe Finance Limited Stock Rallies Above MAStock Price Forecasts & High Return Capital Gain - earlytimes.in
Supernus Pharmaceuticals (SUPN) Is Down 17.4% After Raising 2025 Guidance Amid Margin and Supply Pressures – Has the Bull Case Changed? - Sahm
Is Supernus Pharmaceuticals Inc a good long term investmentChart Pattern Recognition & Small Budget Trading Portfolio - earlytimes.in
What analysts say about Supernus Pharmaceuticals Inc stockEconomic Data Impact & Outstanding Return Stocks - earlytimes.in
SUPN insider Form 4 shows 15,000-share option exercise at $12.98 - Stock Titan
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 - Yahoo Finance
Healthcare Stocks Analysis 2025: COO & SUPN to Sell, HCA to BuyNews and Statistics - IndexBox
Assessing Supernus Pharmaceuticals (SUPN) Valuation as Shares Hold Steady Following Period of Range-Bound Trading - Sahm
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
0.37%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):